Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer / 生物医学工程学杂志
Journal of Biomedical Engineering
;
(6): 1263-1268, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-970666
ABSTRACT
Prostate cancer is the most common malignant tumor in male urinary system, and the morbidity and mortality rate are increasing year by year. Traditional imaging examinations have some limitations in the diagnosis of prostate cancer, and the advent of molecular imaging probes and imaging technology have provided new ideas for the integration of diagnosis and treatment of prostate cancer. In recent years, prostate-specific membrane antigen (PSMA) has attracted much attention as a target for imaging and treatment of prostate cancer. PSMA ligand positron emission tomography (PET) has important reference value in the diagnosis, initial staging, detection of biochemical recurrence and metastasis, clinical decision-making guidance and efficacy evaluation of prostate cancer. This article briefly reviews the clinical research and application progress on PSMA ligand PET imaging in prostate cancer in recent years, so as to raise the efficiency of clinical applications.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Próstata
/
Neoplasias de la Próstata
/
Tomografía de Emisión de Positrones
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
/
Ligandos
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
Journal of Biomedical Engineering
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS